References
- Bate, A,Reynolds, RF,Caubel, P. The hope, hype and reality of Big Data for pharmacovigilance. Ther Adv Drug Saf. 2018;9:5–11.
- Ventola, CL. Big data and pharmacovigilance: data mining for adverse drug events and interactions. Pharm Ther. 2018;43(6):340.
- Hussain, R,Hassali, MA. Current status and future prospects of pharmacovigilance in Pakistan. J Pharm Policy Prac. 2019;12(1):1–3.
- Hussain, R,Hassali, MA,Babar, ZUD. Medicines safety in the globalized context. In: Global pharmaceutical policy. Singapore: Palgrave Macmillan; 2020. p. 1–28.
- Hauben, M,Hartford, CG. Artificial intelligence in pharmacovigilance: scoping points to consider. Clin Ther. 2021. https://doi.org/10.1016/j.clinthera.2020.12.014.
- Keane, PA,Topol, EJ. AI-facilitated health care requires education of clinicians. Lancet. 2021;397(10281):1254.
- Harpaz, R,DuMouchel, W,Shah, NH,Madigan, D,Ryan, P,Friedman, C. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin Pharmacol Ther. 2012;91(6):1010–21.
- Reps, JM,Garibaldi, JM,Aickelin, U,Gibson, JE,Hubbard, RB. A supervised adverse drug reaction signalling framework imitating Bradford Hill’s causality considerations. J Biomed Inform. 2015;56:356–68.
- Nikfarjam, A,Sarker, A,O’Connor, K,Ginn, R,Gonzalez, G. Pharmacovigilance from social media: mining adverse drug reaction mentions using sequence labeling with word embedding cluster features. J Am Med Inform Assoc. 2015;22(3):671–81.
- Sarker, A,Gonzalez, G. Portable automatic text classification for adverse drug reaction detection via multi-corpus training. J Biomed Inform. 2015;53:196–207.
- De Rosa M, Fenza G, Gallo A, Gallo M, Loia V. Pharmacovigilance in the era of social media: discovering adverse drug events cross-relating Twitter and PubMed. Future Gen Comput Syst. 2021;114:394–402. ISSN 0167-739X. https://doi.org/10.1016/j.future.2020.08.020.
- Joppi, R,Bertele, V,Garattini, S. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU. Eur J Clin Pharmacol. 2013;69(1009–1024):11.
- Price, J. What can big data offer the pharmacovigilance of orphan drugs? Clin Ther. 2016;38(12):2533–45.
- Li, J. Unexpected opportunities for innovators in the post COVID world. https://blog.usejournal.com/unexpected-opportunities-for-entrepreneurs-in-the-covid-19-world-fd3eac2a441a. Posted May 2, 2020. Accessed 22 Dec 2020.
- Royster, K. Friedman lab finds unexpected opportunities in COVID adjusted research activities. https://as.vanderbilt.edu/news/2020/11/30/friedman-lab-finds-unexpected-opportunities-in-covid-adjusted-research-activities/. Posted November 30, 2020. Accessed 24 Dec 2020.
- Beninger, P. Influence of COVID-19 on the pharmacovigilance workforce of the future. Clin Ther. 2021. https://doi.org/10.1016/j.clinthera.2020.12.019.